Abstract
We have identified SRT2104 (4) as the first direct synthetic SIRT1 activator clinical candidate. The compound was derived from the optimization of a previously described imidazo[1,2-b]thiazole scaffold. SRT2104 was selected as a development candidate based on a combination of biochemical activity and pharmacokinetic profile. The in vivo characteristics of SRT2104 were superior to those of analogues with similar activation profiles. The overall preclinical profile suggests that the compound has potential to provide therapeutic benefit in a clinical setting.
Keywords: Activator, Imidazothiazole, SIRT1, Sirtuin, SRT1720, SRT2104.
Letters in Drug Design & Discovery
Title:The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate
Volume: 10 Issue: 9
Author(s): Meghan Duncan, Robert B. Perni, James L. Ellis, George P. Vlasuk, Michael R. Jirousek, Joseph J. Nunes, Jill C. Milne, Peter J. Elliot, Vipin Suri, Akanksha Gupta, Kristina Kriksciukaite, Marie Yeager, Pui Yee Ng, Angela Tornblom, Siva Lavu, Jesse J. Smith, Jeffrey Song, Thomas V. Riera, David P. Carney, Amy V. Lynch, Christopher J. Oalmann, Chi B. Vu, Jeremy S. Disch and Jean E. Bemis
Affiliation:
Keywords: Activator, Imidazothiazole, SIRT1, Sirtuin, SRT1720, SRT2104.
Abstract: We have identified SRT2104 (4) as the first direct synthetic SIRT1 activator clinical candidate. The compound was derived from the optimization of a previously described imidazo[1,2-b]thiazole scaffold. SRT2104 was selected as a development candidate based on a combination of biochemical activity and pharmacokinetic profile. The in vivo characteristics of SRT2104 were superior to those of analogues with similar activation profiles. The overall preclinical profile suggests that the compound has potential to provide therapeutic benefit in a clinical setting.
Export Options
About this article
Cite this article as:
Duncan Meghan, Perni B. Robert, Ellis L. James, Vlasuk P. George, Jirousek R. Michael, Nunes J. Joseph, Milne C. Jill, Elliot J. Peter, Suri Vipin, Gupta Akanksha, Kriksciukaite Kristina, Yeager Marie, Ng Yee Pui, Tornblom Angela, Lavu Siva, Smith J. Jesse, Song Jeffrey, Riera V. Thomas, Carney P. David, Lynch V. Amy, Oalmann J. Christopher, Vu B. Chi, Disch S. Jeremy and Bemis E. Jean, The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate, Letters in Drug Design & Discovery 2013; 10 (9) . https://dx.doi.org/10.2174/15701808113100990021
DOI https://dx.doi.org/10.2174/15701808113100990021 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Molecular Targets for Systemic Lupus Erythematosus and Other Immune-Complex and T-Cell Mediated Autoimmune Diseases - Update
Medicinal Chemistry Reviews - Online (Discontinued) Plumbagin Inhibits Breast Tumor Bone Metastasis and Osteolysis by Modulating the Tumor-Bone Microenvironment
Current Molecular Medicine Ginger and Heart Health: From Mechanisms to Therapeutics
Current Molecular Pharmacology Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Quantitative Structure-Activity Relationship (QSAR) Analysis to Predict Drug-Drug Interactions of ABC Transporter ABCG2
Mini-Reviews in Medicinal Chemistry Development of Folate-Conjugated PEGylated Poly (d,l-lactide-co-glycolide) Nanoparticulate Carrier for Docetaxel
Current Nanoscience Ipilimumab Targeting CD28-CTLA-4 Axis: New Hope in the Treatment of Melanoma
Current Topics in Medicinal Chemistry Antibody Fusion Proteins: Applications in Brain Targeting
Current Medicinal Chemistry - Central Nervous System Agents Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot topic: TRP Channels: From Understanding to Action (Guest Editor: Viktorie Vlachova)]
Current Pharmaceutical Biotechnology Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Current Signal Transduction Therapy for Brain Tumors Review Article
Current Signal Transduction Therapy Lentiviral Vectors for Anti-Tumor Immunotherapy
Current Gene Therapy New Pharmacological Approaches in Infants with Hypoxic-Ischemic Encephalopathy
Current Pharmaceutical Design YB-1 Activities in Oncogenesis: Transcription and Translation
Current Cancer Therapy Reviews Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies
Current Cancer Drug Targets Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design